Loading...
*  Breast cancer classification
Mc Ilroy M, Fleming FJ, Buggy Y, Hill AD, Young LS (December 2006). "Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 ... The medical utility of potential biomarkers of tamoxifen responsiveness such as HOXB13, PAX2, and estrogen receptor (ER) alpha ... Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial. 33rd ... 2010;12(206) "Study sheds new light on tamoxifen resistance". CORDIS : News. 2008-11-13. Hurtado A, Holmes KA, Geistlinger TR, ...
*  Exemestane
2007). "Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): ... Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day ... 25 mg/day for 2-3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the ... of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen ...
*  Toremifene
Unlike tamoxifen, toremifene is not a prodrug and does not depend on metabolism by CYP2D6 for bioactivation; hence, it may be ... Toremifene has been found to be effective in the treatment of breast pain and may be a better drug than tamoxifen for this ... The drug is very similar to tamoxifen and shares most of its properties. There are some indications that it may be safer than ... Mao C, Yang ZY, He BF, Liu S, Zhou JH, Luo RC, Chen Q, Tang JL (2012). "Toremifene versus tamoxifen for advanced breast cancer ...
*  Metastatic breast cancer
For estrogen-receptor-positive metastatic breast carcinoma the first line of therapy is often tamoxifen or another anti- ... external-beam radiotherapy followed by tamoxifen or another anti-estrogen may be sufficient to control disease, at least ...
*  Tamoxifen
When tamoxifen was launched as a drug, it was thought that tamoxifen would act as an ER antagonist in all tissue, including ... As of 2004, tamoxifen was the world's largest selling hormonal drug for the treatment of breast cancer. Tamoxifen is used as a ... Tamoxifen has been proposed as part of a treatment plan for Riedel's thyroiditis. Tamoxifen has been shown to be effective in ... Hence tamoxifen's tissue selective action directly led to the formulation of the concept of SERMs. In contrast tamoxifen ...
*  Study of Tamoxifen and Raloxifene
"Raloxifene or tamoxifen: Which is the right drug for you?", USA Today, April 17, 2006 "Raloxifene, Tamoxifen Both Guard Against ... "Study of Tamoxifen and Raloxifene (STAR)". Columbia St. Mary's. "Teleconference: Study of Tamoxifen and Raloxifene (STAR) P-2 ... "Study of Tamoxifen and Raloxifene (STAR)". Weill Cornell Medical College. "Osteoporosis drug equals tamoxifen in preventing ... The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial designed determine how the drug raloxifene compares with the ...
*  DMOZ - Health: Pharmacy: Drugs and Medications: T: Tamoxifen
breastcancer.org: Tamoxifen Offers information about tamoxifen as a treatment for reducing the risk of breast cancer recurrence ...
*  John Katzenellenbogen
A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen". Journal of ... Robertson, D. W.; Katzenellenbogen, J. A.; Long, D. J.; Rorke, E. A.; Katzenellenbogen, B. S. (January 1982). "Tamoxifen ... tamoxifen aziridine) in the human estrogen receptor". The Journal of Biological Chemistry. 264 (29): 17476-17485. ISSN 0021- ... "Tamoxifen aziridines: effective inactivators of the estrogen receptor". Endocrinology. 109 (4): 1298-1300. doi:10.1210/endo-109 ...
*  Idoxifene
"Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent". J. Med. Chem. 32 (12): 2527-33. PMID 2585441. ...
*  Estrogen receptor
ER status is used to determine sensitivity of breast cancer lesions to tamoxifen and aromatase inhibitors. Another SERM, ... Clemons M, Danson S, Howell A (Aug 2002). "Tamoxifen ("Nolvadex"): a review". Cancer Treatment Reviews. 28 (4): 165-80. doi: ... Endocrine therapy for breast cancer involves selective estrogen receptor modulators (SERMS), such as tamoxifen, which behave as ... However, de novo resistance to endocrine therapy undermines the efficacy of using competitive inhibitors like tamoxifen. ...
*  Clomifene
... has been found to be useful in the treatment of some cases of gynecomastia but it is not as effective as tamoxifen or ... Maximov, Philipp Y.; McDaniel, Russell E.; Jordan, V. Craig (2013). "Tamoxifen Goes Forward Alone". Milestones in Drug Therapy ...
*  Somatic evolution in cancer
Osborne CK; Osborne, C. Kent (November 1998). "Tamoxifen in the treatment of breast cancer". N. Engl. J. Med. 339 (22): 1609-18 ... Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD (September 2007). "CYP2D6 polymorphisms and the impact on tamoxifen therapy ... Ring A, Dowsett M (December 2004). "Mechanisms of tamoxifen resistance". Endocr. Relat. Cancer. 11 (4): 643-58. doi:10.1677/erc ... Reduced metabolic activation of tamoxifenPolymorphisms in CYP2D6 show variable rates of conversion of tamoxifen to its ...
*  Riedel's thyroiditis
Tamoxifen has been proposed as part of a treatment plan. Treatment is directed to surgical relief of compressive symptoms. ... Tamoxifen may also be beneficial. -Harrison's principle of internal medicine, 17th The type of surgery which is indicated here ... Dabelic N, Jukic T, Labar Z, Novosel SA, Matesa N, Kusic Z (April 2003). "Riedel's thyroiditis treated with tamoxifen" (PDF). ...
*  Hormone receptor positive breast tumor
Tamoxifen Raloxifene DeVita, Vincent T.; Lawrence, Theodore S.; Rosenberg, Steven A.; Robert A. Weinberg; Ronald A. DePinho ( ... Legha SS (August 1988). "Tamoxifen in the treatment of breast cancer". Ann. Intern. Med. 109 (3): 219-28. doi:10.7326/0003-4819 ...
*  Prasterone
... may promote tamoxifen resistance. Patients on hormone replacement therapy may have more estrogen-related side ...
*  Triphenylethylene
The tamoxifen metabolite and aromatase inhibitor norendoxifen is also a TPE derivative. In addition to their estrogenic ... 95-. ISBN 978-1-59259-152-7. Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering ... activity, various TPE derivatives like tamoxifen and clomifene have been found to act as protein kinase C inhibitors. List of ...
*  Ethamoxytriphetol
5-. ISBN 978-3-527-65110-8. Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering ... and it led to the development of the highly successful tamoxifen for this indication a decade later. The drug was also ... which includes clomifene and tamoxifen. The drug, a derivative of the cholesterol-lowering agent triparanol (MER-29) (which ...
*  Nonsteroidal estrogen
Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering Medicine in Breast Cancer. ... with triphenylethylenes like tamoxifen and clomifene having been derived from DES, and these drugs remain widely used in ... tetrahydrochrysene SERMs like tamoxifen and raloxifene can also be considered to be nonsteroidal estrogens in some tissues. ...
*  Zindoxifene
1300-. ISBN 978-1-4757-2085-3. Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering ...
*  Triphenylchloroethylene
23-. ISBN 978-0-299-10480-1. Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering ...
*  High-dose estrogen
In the 1970s, the antiestrogen tamoxifen was found to be effective for the treatment of breast cancer and was introduced for ... Comparative studies found that the two therapies showed equivalent effectiveness, but that tamoxifen had reduced toxicity. As a ... 56-. ISBN 978-0-387-69179-4. Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering ...
*  2,8-Dihydroxyhexahydrochrysene
Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science & Business Media. pp. 4-. ISBN 978-3-0348-0664-0. Virgil ...
*  Dianol
Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering Medicine in Breast Cancer. ...
*  Antiestrogen
Ethamoxytriphetol (MER-25) was the first antagonist of the ER to be discovered, followed by clomifene and tamoxifen. " ... Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering Medicine in Breast Cancer. ... Antiestrogens include selective estrogen receptor modulators (SERMs) like tamoxifen, clomifene, and raloxifene, the ER silent ...
*  Diethylstilbestrol
ISBN 978-0-12-417213-5. Maximov PY, McDaniel RE, Jordan VC (23 July 2013). Tamoxifen: Pioneering Medicine in Breast Cancer. ... when the FDA approved tamoxifen, a selective estrogen receptor modulator with efficacy similar to DES but fewer side effects. ... "Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer". The New ...